Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study

被引：0
|
作者：
Hofmeister, Craig C.
Chari, Ajai
Cohen, Yael
Spencer, Andrew
Voorhees, Peter M.
Estell, Jane
Venner, Christopher P.
Sandhu, Irwindeep
Jenner, Matthew W.
Williams, Cathy
Cavo, Michele
Van de Donk, Niels W. C. J.
Beksac, Meral
Kuppens, Steven
Bandekar, Rajesh
Neff, Tobias
Heuck, Christoph
Qi, Ming
Goldschmidt, Hartmut
Landgren, Ola
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
510
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
    San-Miguel, Jesus
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Liu, Kevin
    Hellemans, Peter
    Masterson, Tara
    Clemens, Pamela L.
    Luo, Man
    Farnsworth, Andrew
    Nahi, Hareth
    Chari, Ajai
    HAEMATOLOGICA, 2021, 106 (06) : 1725 - 1732
  • [22] A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety
    Nadeem, Omar
    Redd, Robert
    Stampleman, Laura V.
    Matous, Jeffrey V.
    Yee, Andrew J.
    Zonder, Jeffrey A.
    Kin, Andrew
    Rosenblatt, Jacalyn
    Bustoros, Mark
    Prescott, Julia
    Savell, Alexandra
    Guimond, Kathleen
    Frey, Erin
    Styles, Rachel
    Bielawski, Adrienne
    Boehner, Cody J.
    Kham, Nang
    Sperling, Adam S.
    Bianchi, Giada
    Laubach, Jacob P.
    Castillo, Jorge J.
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Trippa, Lorenzo
    Ghobrial, Irene M.
    BLOOD, 2019, 134
  • [23] A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
    Stakiw, Julie
    Kodad, Shruthi
    LeBlanc, Richard
    Sebag, Michael
    Hay, Annette E.
    Kukreti, Vishal
    Cote, Julie
    Camacho, Fernando
    Fu, Molei
    Gul, Engin
    Reece, Donna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (07): : 484 - 490
  • [24] AN OPEN-LABEL, MULTICENTER, PHASE 1B STUDY OF DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE AND WITH BACKBONE REGIMENS IN PATIENTS WITH MULTIPLE MYELOMA
    Mateos, M. V.
    Moreau, P.
    Comenzo, R.
    Blade, J.
    Benboubker, L.
    de la Rubia, J.
    Facon, T.
    Fay, J.
    Qin, X.
    Masterson, T.
    Schecter, J.
    Ahmadi, T.
    San-Miguel, J.
    HAEMATOLOGICA, 2015, 100 : 84 - 84
  • [25] Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES)
    Chari, Ajai
    Goldschmidt, Hartmut
    San-Miguel, Jesus
    McCarthy, Helen
    Suzuki, Kenshi
    Hungria, Vania
    Sureda Balari, Anna
    Perrot, Aurore
    Hulin, Cyrille
    Magen, Hila
    Iida, Shinsuke
    Maisnar, Vladimir
    Karlin, Lionel
    Pour, Ludek
    Parasrampuria, Dolly
    Masterson, Tara
    Kosh, Michele
    Yang, Shiyi
    Qi, Ming
    Carson, Robin
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E16 - E17
  • [26] A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
    Zonder, Jeffrey A.
    Mohrbacher, Ann F.
    Singhal, Seema
    van Rhee, Frits
    Bensinger, William I.
    Ding, Han
    Fry, John
    Afar, Daniel E. H.
    Singhal, Anil K.
    BLOOD, 2012, 120 (03) : 552 - 559
  • [27] Influence of Lenalidomide Treatment on Immune Effector Cells From High-Risk Smoldering Multiple Myeloma (SMM) Patients
    Paiva, Bruno
    Victoria Mateos, Maria
    Lopez-Corral, Lucia
    Vidriales, Maria-Belen
    Hernandez, Miguel T.
    Bargay, Joan
    de Arriba, Felipe
    De la Rubia, Javier
    Teruel, Ana-Isabel
    Giraldo, Pilar
    Rosinol, Laura
    Prosper, Felipe
    Oriol, Albert
    Hernandez, Jose
    Esteves, Graca
    da Costa, Fernando Leal
    Jose Lahuerta, Juan
    Blade, Joan
    San Miguel, Jesus F.
    BLOOD, 2011, 118 (21) : 1686 - 1686
  • [28] A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma.
    Zonder, Jeffrey A.
    Raje, Noopur S.
    Scott, Emma Catherine
    Hofmeister, Craig C.
    Lendvai, Nikoletta
    Anderson, Larry Don
    Hari, Parameswaran
    Orloff, Gregory Joshua
    Berdeja, Jesus G.
    Singhal, Seema
    Craig, Michael
    Valent, Jason Neil
    Ptaszynski, Mieke
    Schreiber, Jennifer
    Aitchison, Roger
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
    Groen, Kaz
    Stege, Claudia A. M.
    Nasserinejad, Kazem
    de Heer, Koen
    van Kampen, Roel J. W.
    Leys, Rineke B. L.
    Thielen, Noortje
    Westerman, Matthijs
    Wu, Ka-Lung
    Ludwig, Inge
    Issa, Djamila E.
    Velders, Gerjo A.
    Vekemans, Marie-Christiane
    Timmers, Gert-Jan
    de Boer, Fransien
    Tick, Lidwine W.
    Verbrugge, Annelies
    Buitenhuis, Danny
    Cunha, Sonia M.
    van der Spek, Ellen
    de Waal, Esther G. M.
    Sohne, Maaike
    Sonneveld, Pieter
    Nijhof, Inger S.
    Klein, Saskia K.
    van der Donk, Niels W. C. J.
    Levin, Mark-David
    Ypma, Paula F.
    Zweegman, Sonja
    ECLINICALMEDICINE, 2023, 63
  • [30] Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
    Chari, Ajai
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Nahi, Hareth
    Tang, Jie
    Hellemans, Peter
    Tromp, Brenda
    Clemens, Pamela L.
    Farnsworth, Andrew
    San-Miguel, Jesus F.
    Usmani, Saad Z.
    BLOOD, 2018, 132
12345